Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lufax Holding Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.27 (market cap $29.60B), while Lufax Holding Ltd trades at $1.56 (market cap $2.41B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.3× Lufax Holding Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | LU | |
|---|---|---|
Market Cap | $29.60B | $2.41B |
Sector | Health | Technology |
52-Week High | $491.22 | $4.40 |
52-Week Low | $205.48 | $1.23 |
Enterprise Value | $27.56B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
